![187430@2x.png](https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/clinicaltrials/187430@2x.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/clinicaltrials/187430@2x.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/clinicaltrials/187430@2x.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Erlotinib clinical trials
Erlotinib is a selective, reversible tyrosine kinase inhibitor which binds with high affinity to the mutated EGFR receptor, thus preventing promotion of tumour cell survival and proliferation.1
![page_3@2x.png](https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/clinicaltrials/page_3@2x.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/clinicaltrials/page_3@2x.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/tarceva/en-GB/images/si/clinicaltrials/page_3@2x.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Erlotinib clinical trials
Erlotinib is a selective, reversible tyrosine kinase inhibitor which binds with high affinity to the mutated EGFR receptor, thus preventing promotion of tumour cell survival and proliferation.1